ROLEXROLEXROLEXROLEXROLEXROLEXROLEXROLEXROLEXROLEXROLEXROLEX
4 December 2021, 04:39 AM | #8701 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
|
4 December 2021, 04:44 AM | #8702 | |
"TRF" Member
Join Date: Nov 2017
Location: SoCal
Watch: Rolex & AP
Posts: 4,535
|
Quote:
|
|
4 December 2021, 04:44 AM | #8703 | |
"TRF" Member
Join Date: Jan 2010
Location: CT
Watch: 16710,116520,SLA19
Posts: 405
|
Talking Stocks 2.0
Quote:
Ha Ha. Its only 3 contracts; one for each one of my accounts. I also hear that you can buy cheaper first and then sell to flush the old expensive lots out using FIFO during this time of the year. Just have the last transaction as a sell registered so there is no higher previous cost basis to add to a buy transaction. Maybe someone can correct me if I am wrong.. |
|
4 December 2021, 04:47 AM | #8704 | |
"TRF" Member
Join Date: Jan 2010
Location: CT
Watch: 16710,116520,SLA19
Posts: 405
|
Talking Stocks 2.0
Quote:
I guess I will find out. Thought because the ticker symbols are not the same between shares and derivatives so no way to “marry” them together for wash sale accounting. |
|
4 December 2021, 05:00 AM | #8705 |
"TRF" Member
Join Date: Nov 2017
Location: SoCal
Watch: Rolex & AP
Posts: 4,535
|
From my understanding, if the new purchase is “substantially identical” to the original loss, then it triggers the wash. I could be wrong but it’s what I’ve thought to be true from what I’ve looked into before. Guess we need to get to the bottom of this to know for certain.
|
4 December 2021, 05:03 AM | #8706 | |
"TRF" Member
Join Date: Jan 2010
Location: CT
Watch: 16710,116520,SLA19
Posts: 405
|
Talking Stocks 2.0
Quote:
1. So that is for a new purchase which triggers wash sale process. 2. What about buying first at a lower price then sell? |
|
4 December 2021, 05:30 AM | #8707 | |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
Quote:
|
|
4 December 2021, 06:23 AM | #8708 |
"TRF" Member
Join Date: Mar 2011
Real Name: B.
Location: Beverly Hills, CA
Posts: 3,330
|
some solid news here today on SABR, BIG multi million dollar 10 year partnership with American Express, will go above and beyond covering the loss in expedia business. See this as a really positive catalyst, too bad it is announced on a blood bath of a day.
Sabre and American Express Global Business Travel announce multi-year technology partnership to advance corporate travel GBT plans to make multi-million dollar long-term annual investment in joint technology development with Sabre - Two thought-leading companies plan to develop distribution ecosystem for corporate travel industry - New agreement anticipates meaningful growth in GDS bookings through Sabre
__________________
Richard Mille RG RM030 || Richard Mille RM72ti || AP 26240 50TH Green Royal Oak Chrono || AP Royal Oak Blue JUMBO SS 15202ST || AP ROO Diver Green 15720ST || ♕ Rolex Platinum Daytona Diamond 116506 || Cartier Santos |
4 December 2021, 06:47 AM | #8709 |
"TRF" Member
Join Date: Sep 2016
Location: Miami
Posts: 1,618
|
Took some nibbles on a few names today including MTTR (long long term hold) but want to hold on the sidelines for a couple more trading sessions.
Good thing is the transition from this thread to the Whisky thread will be seamless tonight…
__________________
AP ROC 26315or; AP RO 15450st; Vacheron Fiftysix; Day Date RG 228235 Olive; Daytona YG 116528; Daytona YG Oysterflex 116518; Cartier Santos de Cartier Rose Gold; Panerai PAM 0048; IWC Portofino Chrono; Girard-Perregaux Richeville |
4 December 2021, 06:49 AM | #8710 | |
"TRF" Member
Join Date: Nov 2017
Location: SoCal
Watch: Rolex & AP
Posts: 4,535
|
Quote:
|
|
4 December 2021, 07:02 AM | #8711 | |
2024 Pledge Member
Join Date: Apr 2015
Location: USA
Watch: 5 digit models
Posts: 1,515
|
Quote:
https://fairmark.com/investment-taxa...s-and-options/ |
|
4 December 2021, 07:09 AM | #8712 | |
"TRF" Member
Join Date: Jan 2010
Location: CT
Watch: 16710,116520,SLA19
Posts: 405
|
Talking Stocks 2.0
Quote:
So its this author’s opinion? Depends on what broker shows and go with it. |
|
4 December 2021, 07:09 AM | #8713 | |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
Quote:
|
|
4 December 2021, 07:13 AM | #8714 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
yeah i don't usually bother reading them either, too many numbers lol. i just remember reading about what happens if you close options at a loss to roll them out and checked the document a few days later to see if it counted as a wash sale and it didn't, but i don't know how it would be on other brokers
|
4 December 2021, 09:17 AM | #8715 |
"TRF" Member
Join Date: Feb 2019
Location: Santiago, Chile
Posts: 147
|
|
5 December 2021, 01:23 PM | #8716 |
2024 Pledge Member
Join Date: Nov 2007
Location: San Francisco, CA
Watch: Date & No Date
Posts: 10,842
|
Fear of missing out is replaced by fear of staying in as crowded momentum stocks are purged.
Courtesy of CNBC.
__________________
"You might as well question why we breathe. If we stop breathing, we'll die. If we stop fighting our enemies, the world will die." Paul Henreid as Victor Laszlo in Casablanca |
7 December 2021, 12:39 AM | #8717 |
"TRF" Member
Join Date: Jan 2019
Location: North America
Posts: 2,300
|
|
7 December 2021, 01:02 AM | #8718 |
"TRF" Member
Join Date: Jan 2019
Location: North America
Posts: 2,300
|
Some stocks totally redeeming themselves now lol. What volatility
|
7 December 2021, 04:38 AM | #8719 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
so... blood red tomorrow? lol
|
7 December 2021, 06:02 AM | #8720 |
"TRF" Member
Join Date: Nov 2008
Location: NYC
Posts: 1,605
|
|
7 December 2021, 06:13 AM | #8721 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
|
8 December 2021, 01:26 AM | #8722 |
"TRF" Member
Join Date: Mar 2011
Real Name: B.
Location: Beverly Hills, CA
Posts: 3,330
|
Green EVERYWHERE today boys on back to back days too, hope I am not dreaming.
__________________
Richard Mille RG RM030 || Richard Mille RM72ti || AP 26240 50TH Green Royal Oak Chrono || AP Royal Oak Blue JUMBO SS 15202ST || AP ROO Diver Green 15720ST || ♕ Rolex Platinum Daytona Diamond 116506 || Cartier Santos |
8 December 2021, 01:36 AM | #8723 |
2024 Pledge Member
Join Date: Jun 2020
Real Name: Goat
Location: Southwest Florida
Watch: 16613
Posts: 4,782
|
Talking Stocks 2.0
|
8 December 2021, 01:44 AM | #8724 |
"TRF" Member
Join Date: Mar 2011
Real Name: B.
Location: Beverly Hills, CA
Posts: 3,330
|
__________________
Richard Mille RG RM030 || Richard Mille RM72ti || AP 26240 50TH Green Royal Oak Chrono || AP Royal Oak Blue JUMBO SS 15202ST || AP ROO Diver Green 15720ST || ♕ Rolex Platinum Daytona Diamond 116506 || Cartier Santos |
8 December 2021, 01:48 AM | #8725 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
so much green that we even have this :
feels wrong |
8 December 2021, 01:53 AM | #8726 |
"TRF" Member
Join Date: Mar 2011
Real Name: B.
Location: Beverly Hills, CA
Posts: 3,330
|
hahaha I actually hit refresh to make sure it wasn't an error. Any news there? Looks like lower vol run.
__________________
Richard Mille RG RM030 || Richard Mille RM72ti || AP 26240 50TH Green Royal Oak Chrono || AP Royal Oak Blue JUMBO SS 15202ST || AP ROO Diver Green 15720ST || ♕ Rolex Platinum Daytona Diamond 116506 || Cartier Santos |
8 December 2021, 02:00 AM | #8727 |
2024 Pledge Member
Join Date: Jun 2020
Real Name: Goat
Location: Southwest Florida
Watch: 16613
Posts: 4,782
|
|
8 December 2021, 02:10 AM | #8728 |
2024 Pledge Member
Join Date: Oct 2017
Location: nyc
Posts: 6,285
|
|
8 December 2021, 04:22 AM | #8729 |
"TRF" Member
Join Date: Mar 2011
Real Name: B.
Location: Beverly Hills, CA
Posts: 3,330
|
As much as I hate MF, I think this is a great piece highlighting 8 oversold biotechs which are poised for a comeback, especially given how beaten down XBI has been this year. Note the shoutout to AUPH, up 8% today getting ready to breakthrough $21 and ATEC on a nice run. From the below, I have been researching ADAP, AXSM and BCRX.
The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022. 1. Adaptimmune Therapeutics (ADAP) Adaptimmunes's shares are thus trading at less than 2 1/2 times the company's last stated cash position, and close to their 52-week low right now. With multiple partnerships in place and a regulatory filing on the near-term horizon, the stock should roar back to life in 2022. 2. Affimed Therapeutics Affimed Therapeutics ( AFMD 6.31% ), a German cancer immunotherapy company, has seen its shares wilt by 46.5% from their 52-week high set back in the second quarter of 2021. This sharp decline occurred even though the company posted outstanding early-stage trial results for its innate cell engager AFM13 in patients with recurrent or refractory CD30-positive lymphomas earlier this year. Under normal market conditions, this clear-cut win in the clinic probably would have resulted in a sustained rally. Instead, Affimed's shares are being valued at just 1.2 times AFM13's peak sales projection for its first potential indication. This dirt-cheap valuation is the reason Wall Street thinks the biotech's shares could more than double in value over the next 12 months. 3. Amicus Therapeutics Shares of the rare-disease drugmaker Amicus Therapeutics ( FOLD 4.43% ) are down by over 55% from their 52-week high right now. The orphan-drug specialist took a big hit back in February after announcing late-state trial results for its Pompe disease candidate AT-GAA. Since then, Amicus has decided to sally forth with regulatory filings for the therapy in both the E.U. and the United States. What's noteworthy about this stock is that it is presently trading at roughly 5.4 times 2024 projected sales under a worst-case scenario. That might sound like a rich valuation, but it is among the lowest within the highly coveted orphan-drug space. Amicus' stock, in turn, should be among the first to rebound once the negative sentiment surrounding biopharma dissipates. 4. Aurinia Pharmaceuticals Aurinia Pharmaceuticals ( AUPH 6.27% ) stock is off of its 52-week high by a whopping 42.1% at the moment. The autoimmune-disease specialist has reverted to the mean in recent weeks after filing a $250 million mixed-shelf offering with the Securities and Exchange Commission, which some investors took as a sign that a buyout was off the table. Because of this sharp pullback, Aurinia's stock is now trading at only about 2.4 times the 2025 sales projection for its lupus nephritis medication Lupkynis. Buyout or not, Aurinia's shares are arguably a steal at these levels. 5. Axsome Therapeutics Axsome Therapeutics ( AXSM 5.50% ) stock is now trading at a 60% discount compared to its 52-week high. Investors hit the exits on this biotech stock after the FDA notified the company that it couldn't complete a regulatory review for the experimental drug for major depressive disorder AXS-05 due to deficiencies in its regulatory application. Several months later, the FDA has yet to hand down a final decision on AXS-05. On the bright side, management thinks these deficiencies can be addressed during the current review cycle. If true, Axsome's shares ought to mount a furious comeback in 2022. Wall Street, after all, has pegged AXS-05's peak sales for major depressive disorder at a whopping $1.3 billion. 6. Beam Therapeutics The stock of Beam Therapeutics ( BEAM 16.02% ), a clinical-stage genetic base-editing company, has shed 48% of its value relative to its 52-week high in recent weeks. The good news is that Beam hasn't reported any major clinical or regulatory setbacks. Rather, investors seem to be backing away from this biotech mostly because of its sky-high valuation. Beam currently sports a market cap of $4.7 billion. That's definitely a rich valuation for a biotech with an unproven platform, especially for one that is just now entering human trials. That being said, Beam's stock could turn out to be a bargain if its novel genetic base-editing platform strikes gold in the clinic. Data from its first clinical candidate, BEAM-101, should be available sometime in 2022. The company plans on trialing the therapy as a treatment for the rare blood disorder sickle cell disease. 7. BioCryst Pharmaceuticals Shares of BioCryst Pharmaceuticals ( BCRX 8.59% ), a mid-cap rare-disease drugmaker, have slipped by 36% from their 52-week high of late. BioCryst's stock, however, should arguably be moving in the opposite direction based on the blistering sales growth for its hereditary angioedema drug Orladeyo. The biotech's shares are trading at roughly three times Orladeyo's peak sales estimate, and well under three times the net present value for the whole of its pipeline and product portfolio. That's an incredibly cheap valuation for a high-growth pharmaceutical stock. 8. BridgeBio Pharma BridgeBio Pharma ( BBIO 1.30% ) stock is down by a hefty 45.6% relative to its 52-week high at the time of this writing. The company's shares have steadily marched lower in the second half of 2021 due to competitive concerns about its experimental amyloidosis drug, Acoramidis, which is slated to yield data before year's end. While industry insiders are largely expecting this late-stage data to be positive, some analysts aren't convinced that the drug can compete effectively against rival therapies. That's a potentially major problem. Acoramidis is easily BridgeBio's most important value driver, with its net present value estimated at a whopping $3.5 billion, according to a recent report by Evaluate Vantage. BridgeBio's stock could soar if Acoramidis' trial surpasses expectations. Wall Street's current consensus price target, in fact, implies that the biotech's shares could more than double in value over the next 12 months.
__________________
Richard Mille RG RM030 || Richard Mille RM72ti || AP 26240 50TH Green Royal Oak Chrono || AP Royal Oak Blue JUMBO SS 15202ST || AP ROO Diver Green 15720ST || ♕ Rolex Platinum Daytona Diamond 116506 || Cartier Santos |
8 December 2021, 05:30 AM | #8730 |
2024 Pledge Member
Join Date: Apr 2015
Location: USA
Watch: 5 digit models
Posts: 1,515
|
|
Currently Active Users Viewing This Thread: 1 (0 members and 1 guests) | |
Thread Tools | |
Display Modes | |
|
|
*Banners
Of The Month*
This space is provided to horological resources.